Open Biomarkers Journal最新文献_第4页

Stratum Corneum Biomarkers in Atopic Dermatitis: Biological and Spatial Variability 特应性皮炎角膜层生物标志物的生物学和空间变异性

Open Biomarkers Journal Pub Date : 2020-06-16 DOI: 10.2174/1875318302010010047

R. Toncic, S. Kežić, S. L. HadžavdiĆ, B. Marinovic, I. Jakaša

{"title":"Stratum Corneum Biomarkers in Atopic Dermatitis: Biological and Spatial Variability","authors":"R. Toncic, S. Kežić, S. L. HadžavdiĆ, B. Marinovic, I. Jakaša","doi":"10.2174/1875318302010010047","DOIUrl":"https://doi.org/10.2174/1875318302010010047","url":null,"abstract":"Background: Atopic dermatitis is a highly heterogeneous skin disease, mainly affecting children. Introduction of biological therapies has urged the development of biomarkers to facilitate personalized therapy. Stratum corneum biomarkers emerged as a promising non-invasive alternative to skin biopsy, yet validation of spatial and biological variability is essential for their application in clinical research. Objective: To assess spatial and biological variability of stratum corneum biomarkers for atopic dermatitis. Methods: Stratum corneum was collected from 17 atopic dermatitis patients by consecutive application of eight adhesive tapes to a lesional skin site and 2 cm and 4 cm from the lesion. Two non-lesional sites at a 2 cm distance from the same lesion were collected to determine biological variability. Filaggrin degradation products (NMF) were determined by liquid chromatography and thirteen cytokines (IL-4, IL-13, IL-18, IL-31, IL-33, CCL17, CCL22, CCL27, CXCL8, IL-1α, IL-RA, IL-18, IL-22) by multiplex immunoassay. Results: Biomarker levels showed gradual changes from lesional to non-lesional skin sites at 2 cm and 4 cm; magnitude and direction of change were biomarker-specific. Intra-subject variability ranged from 17.3% (NMF) to 85.1% (CXCL8). Biomarker levels from two stratum corneum depths were highly correlated; several biomarkers showed significant depth dependence. Conclusion: Stratum corneum enables non-invasive collection of relevant immune and epidermal biomarkers, but biomarker-specific spatial and biological variability emphasizes the importance of standardized procedures for stratum corneum collection.","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":"10 1","pages":"47-54"},"PeriodicalIF":0.0,"publicationDate":"2020-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46684080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 9

New Insights to Reshape the Management of Patients with Metastatic Breast Cancer - Focus on Overcoming Challenges in HER2 Status Interpretation 重塑癌症转移性乳腺癌患者管理的新见解-专注于克服HER2状态解释的挑战

Open Biomarkers Journal Pub Date : 2020-06-04 DOI: 10.2174/1875318302010010038

K. Rygiel

{"title":"New Insights to Reshape the Management of Patients with Metastatic Breast Cancer - Focus on Overcoming Challenges in HER2 Status Interpretation","authors":"K. Rygiel","doi":"10.2174/1875318302010010038","DOIUrl":"https://doi.org/10.2174/1875318302010010038","url":null,"abstract":"Approximately 20% of invasive Breast Cancers (BCs) are characterized by Human Epidermal growth factor Receptor 2 (HER2) protein overexpression or HER2 gene amplification. HER2 represents a standard diagnostic test and a predictive biomarker for the use of HER2-directed treatments in patients with BC. At present, the HER2 Immunohistochemistry (IHC) assay is applied for screening purposes, and the In Situ Hybridization (ISH) test serves as a confirmation, when HER2 IHC results are equivocal. However, an accurate assessment and interpretation of the HER2 status can be complicated in many women with BC. These difficulties can be attributed to various factors such as HER2 Intratumoral Heterogeneity (ITH) and changes of HER2 in the process of BC metastatic progression or post neoadjuvant Chemotherapy (CHT). In particular, the status of biomarkers (e.g., HER2 and co-expressed Hormone Receptor (HR)) can be altered in patients with metastatic BC and such receptor changes influence the therapeutic responses and clinical outcomes. The goal of this article is to present challenges in the assessment of HER2 expression and to underscore a need for the biomarker status reevaluation in patients with metastatic BC. This mini-review also provides some insights into the interpretation of equivocal HER2 status in women with metastatic BC and discusses the impact of HER2 and HR biomarker conversions on therapeutic decision-making and the patient prognosis in metastatic BC. It is crucial to correctly interpret the HER2 biomarker status and to assess conversions of HER2 and HR in the BC metastatic lesions since timely detection of such alterations is critical to management modifications of individual patients with metastatic BC.","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":"10 1","pages":"38-46"},"PeriodicalIF":0.0,"publicationDate":"2020-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47929482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Utility of New Biomarker-based Predictive Model for Clinical Outcomes Among ST-elevation Myocardial Infarction Patients 新的基于生物标志物的预测模型在ST段抬高型心肌梗死患者临床转归中的应用

Open Biomarkers Journal Pub Date : 2020-05-31 DOI: 10.2174/1875318302010010023

O. Petyunina, M. Kopytsya, A. Berezin

{"title":"The Utility of New Biomarker-based Predictive Model for Clinical Outcomes Among ST-elevation Myocardial Infarction Patients","authors":"O. Petyunina, M. Kopytsya, A. Berezin","doi":"10.2174/1875318302010010023","DOIUrl":"https://doi.org/10.2174/1875318302010010023","url":null,"abstract":"\u0000 \u0000 To determine the discriminative potency of score to prognosticate poor clinical outcomes in ST-Segment Elevation Myocardial Infarction (STEMI) patients.\u0000 \u0000 \u0000 \u0000 From the entire population of STEMI (n=268), we enrolled 177 individuals with acute STEMI who underwent complete revascularization with primary Percutaneous Coronary Intervention (PCI). Clinical assessment, echocardiography, Doppler, and biomarkers’ measure were performed at baseline.\u0000 \u0000 \u0000 \u0000 Combined endpoint (Major Cardiovascular Events - MACEs [composite of cardiovascular death, recurrent myocardial infarction, newly diagnosed Heart Failure] and hospitalization) was determined in 75 patients with acute STEMI population (40.6%). Newly onset heart failure (HF) was reported in 46 patients (26.0%), Cardiovascular (CV) death occurred in 12 patients (6.8%), MACEs were determined in 58 patients (32.8%), and recurrent hospitalization due to CV reasons was found in 17 (9.6%). The conventional risk predictive models were engineered by a combination of TIMI risk score +acute HF Killip class ≥ II + the levels of NT-pro brain natriuretic peptide > 300 pg / mL and troponin >0.05 ng/mL. We developed a new predictive model based on the presentation of T786С genotype of endothelial NO syntase gene (rs 2070744), А1166С in angiotensin-ІІ receptor-1 gene (rs5186) and serum levels of soluble suppressor tumorigenicity ≥35 pg/mL, vascular endothelial growth factor ≤172 pg/mL and macrophage inhibitory factor ≥2792.7 pg/mL. STEMI patients who had >5 score points demonstrated significantly worse prognosis than those who had ≤5 score points.\u0000 \u0000 \u0000 \u0000 Here we have reported that a new original predictive model is better than a conventional model in discriminative ability to predict combined clinical outcome in STEMI patients.\u0000","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2020-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41599896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Talin-1 Gene Expression as a Tumor Marker in Hepatocellular Carcinoma Patients: A Pilot Study 肝细胞癌患者Talin-1基因表达作为肿瘤标志物的初步研究

Open Biomarkers Journal Pub Date : 2020-04-23 DOI: 10.2174/1875318302010010015

A. Mohamed, Naglaa El-Toukhy, D. Ghaith, Ingy Badawy, S. Abdo, M. Elkadeem, Mohamed Mahrous, S. Abd-Elsalam

引用次数: 3

Association Between Vitamin D Receptor Gene Polymorphisms and Helicobacter Pylori Infection 维生素D受体基因多态性与幽门螺杆菌感染的关系

Open Biomarkers Journal Pub Date : 2020-03-20 DOI: 10.2174/1875318302010010008

A. Mohamed, Shorouk Moussa, M. Shaheen, S. Abd-Elsalam, R. Ahmed, S. M. Mostafa, Amina Fouad, H. Alegaily, S. A. Megahed, Y. Abo-Amer

引用次数: 2

Effects of Coronary Angioplasty on Inflammatory Markers and Lipid Profile in Patients with Cardiovascular Disease 冠状动脉血管成形术对心血管疾病患者炎症标志物和脂质分布的影响

Open Biomarkers Journal Pub Date : 2020-02-18 DOI: 10.2174/1875318302010010001

Tathiane Tanajura da Silva, Roque Aras Júnior, Daniel Lima de Moura, Júlio C. A. Santos, Álvaro L. Müller da Fonseca, R. Couto, Fernanda W. M. Lima

引用次数: 0

Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker 肝细胞癌患者血清血管内皮生长因子及其作为肿瘤生物标志物的有效性

Open Biomarkers Journal Pub Date : 2019-12-31 DOI: 10.2174/1875318301909010084

N. Sadik, Nagwa Ahmed, M. Mohamed, O. Ashoush

{"title":"Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker","authors":"N. Sadik, Nagwa Ahmed, M. Mohamed, O. Ashoush","doi":"10.2174/1875318301909010084","DOIUrl":"https://doi.org/10.2174/1875318301909010084","url":null,"abstract":"\u0000 \u0000 Hepatocellular Carcinoma (HCC) is one of the most common cancers associated with deaths worldwide and the presence of valid biomarkers for early diagnosis in high-risk patients can ameliorate the outcome of HCC. Vascular Endothelial Growth Factor (VEGF) has been found to play an essential role in the process of HCC growth and progression.\u0000 \u0000 \u0000 \u0000 Therefore, we evaluated the serum VEGF levels in patients with HCC and liver cirrhosis and estimated its significant value for differentiating HCC patients from liver cirrhosis patients.\u0000 \u0000 \u0000 \u0000 Eighty-one subjects were enrolled in the study, 30 patients had HCC, 31 patients had liver cirrhosis and 20 were healthy control subjects. VEGF and AFP were measured using ELIZA. Abdominal ultrasound and triphasic abdominal computed tomography were performed in all subjects. Receiver Operating Characteristics curve analysis was performed for serum VEGF to determine its validity as a tumor biomarker.\u0000 \u0000 \u0000 \u0000 The median levels of the serum VEGF were highly expressed in the HCC group (418 pg/ml) and the liver cirrhosis group (308 pg/ml) with no significant difference (P = 0.767); however both groups showed a significant increase compared to the control group (0.8 pg/ml, P <0.000). Serum VEGF showed high sensitivity (100%) and high specificity (100%) in differentiating HCC patients from controls with a cut-off value of ≥ 64.2 pg/ml, although it showed low sensitivity (29.2%) and specificity (85.7%) for differentiating HCC patients from liver cirrhosis patients.\u0000 \u0000 \u0000 \u0000 VEGF can be used as a reliable biomarker for differentiating HCC patients from healthy subjects but it can't be used as a reliable biomarker for differentiating HCC patients from high-risk patients as liver cirrhosis. The elevated serum VEGF levels in HCC and liver cirrhosis patients can elucidate the crucial role of angiogenesis in HCC and liver cirrhosis.\u0000","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47700514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The Teratogenic Mechanism of Echinochrome as a Hypoglycemic Agent on Wistar Rats 棘球蚴色素作为降血糖剂对Wistar大鼠致畸机制的研究

Open Biomarkers Journal Pub Date : 2019-12-31 DOI: 10.2174/1875318301909010079

A. Mohamed, Eman Y. Salah EL Din, Neveen G. A. Farag, A. Tawfik

引用次数: 2

Assessment of Hepatic Steatosis in Patients with Chronic Hepatitis B Using Fibroscan and its Relation to Insulin Resistance 纤维扫描评价慢性乙型肝炎肝脂肪变性及其与胰岛素抵抗的关系

Open Biomarkers Journal Pub Date : 2019-11-05 DOI: 10.2174/1875318301909010070

Reham M. Gameaa, N. Hawash, R. Badawi, S. Abd-Elsalam, Gamal K. Kasem, Elsaid Wasfy

{"title":"Assessment of Hepatic Steatosis in Patients with Chronic Hepatitis B Using Fibroscan and its Relation to Insulin Resistance","authors":"Reham M. Gameaa, N. Hawash, R. Badawi, S. Abd-Elsalam, Gamal K. Kasem, Elsaid Wasfy","doi":"10.2174/1875318301909010070","DOIUrl":"https://doi.org/10.2174/1875318301909010070","url":null,"abstract":"\u0000 \u0000 Simple hepatic steatosis is a benign condition, but it may cause serious liver damage as it may lead to steatohepatitis, fibrosis and cirrhosis. The Controlled Attenuation Parameter (CAP) of fibroscan assesses hepatic steatosis. The aim of this work was to assess hepatic steatosis in patients with chronic hepatitis B infection using FibroScan and to detect its relation to insulin resistance.\u0000 \u0000 \u0000 \u0000 Seventy-seven patients with chronic HBV were enrolled in this study. Body mass index, complete lipid profile, fasting insulin, HOMA-IR, pelviabdominal ultrasound and fibroscan were assessed in all patients.\u0000 \u0000 \u0000 \u0000 According to the presence of significant steatosis, seventy-seven patients enrolled in this study were divided into different groups, such as group I 47 patients (61.04%) with CHB virus infection with non-significant steatosis and group II 30 patients (38.96%) with CHB infection with significant steatosis. There was a statistically significant increase in fasting insulin and HOMA-IR in group II (p-value <0.001). CAP results ranged from 100-396 db/m with no significant difference in liver stiffness measurements in two studied groups (P value= 0.886). There was a significant positive correlation between the degree of hepatic steatosis measured by fibroscan and fasting insulin blood level, HOMA-IR, serum cholesterol and LDL. At cutoff > 222 db/m steatosis measured by fibroscan had a sensitivity of 63.33% and specificity of 82.35% for the detection of insulin resistance.\u0000 \u0000 \u0000 \u0000 In CHB infected patients, steatosis measurement by fibroscan was a strong predictor of Insulin Resistance (IR) and vice versa.\u0000","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43109206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of Different Biomarkers in the Diagnosis of Drug-induced Liver Injury 不同生物标志物在药物性肝损伤诊断中的应用

Open Biomarkers Journal Pub Date : 2019-09-30 DOI: 10.2174/1875318301909010055

Monika Sharma, Ishita Yadav, C. Sharma

{"title":"Applications of Different Biomarkers in the Diagnosis of Drug-induced Liver Injury","authors":"Monika Sharma, Ishita Yadav, C. Sharma","doi":"10.2174/1875318301909010055","DOIUrl":"https://doi.org/10.2174/1875318301909010055","url":null,"abstract":"Biomarkers perform a significant function in the process of drug development. Biomarkers have been utilized in the safety assessment of drugs in clinical practice and also for personalization of medicines. To recognize the relation among considerable biological processes as well as clinical outcomes, it is important to increase our potential of treatments for all ailments, in addition to our understanding of normal and healthy physiology. Since the 1980s, using biomarkers is essential for substitutional results in long term assessments of main maladies, for example, cancer, as well as illness related to the heart. Now a days, biomarkers are highly important for unifying discovery of the drug and day by day improvements. The importance of biomarkers is increasing gradually with the advancement of novel therapeutics for the treatment and prevention of a broad range of diseases in order to overcome hepatotoxicity. These biomarkers are extensively used for the identification of disease and the field of medical research. The use of biomarkers in clinical as well as basic research has been promoted rapidly by the different drug regulation authorities for better outcomes in the future.","PeriodicalId":39398,"journal":{"name":"Open Biomarkers Journal","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43192659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0